In survival analysis, high MMP-2 expression was associated with poorer outcome in patients with grade II-IV astrocytomas (HR 2.54; 95% CI 1.86–3.48; p<0.001) (Fig 4D). This evidence concerns the gene MMP2 and astrocytoma (excluding glioblastoma).